MONON BIOVENTURES, LLC
Biotech · Private
Triple-specific CAR-NK cell immunotherapy for glioblastoma
- Grants
- $2.0M
- 5 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2017201820192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · A Novel Probiotic Platform to Treat Necrotizing Enterocolitis | $331,395 | |
| Federal grant | Department of Health and Human Services · Phase II · Soluble, solution-stable phospho-glucagon for hypoglycemic rescue | $298,152 | |
| Federal grant | Department of Health and Human Services · Phase II · Soluble, solution-stable phospho-glucagon for hypoglycemic rescue | $495,101 | |
| Federal grant | Department of Health and Human Services · Phase II · Soluble, solution-stable phospho-glucagon for hypoglycemic rescue | $504,770 | |
| Federal grant | Department of Health and Human Services · Phase I · Off-the-shelf engineered NK cells to treat glioblastoma | $399,314 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2091 | CNS Pharmaceuticals, Inc. | — | $23M |
| 2092 | CAYMAN CHEMICAL COMPANY, INCORPORATED | — | — |
| 2093 | Kairos Pharma, LTD. | — | $4.2M |
| 2094 | MONON BIOVENTURES, LLC | — | — |
| 2095 | Sequor Pharamaceuticals LLC | — | — |
| 2096 | MIRNA ANALYTICS, LLC | — | — |
| 2097 | Marathoner Biosciences | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Modified Glucagon Molecues And Formulations With Oxidation Resistance And Methods And Kits Of Employing The Sameapplication
- Modified Glucagon Molecules And Formulations With Oxidation Resistance And Methods And Kits Of Employing The Sameapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.